Oroscomucoid like protein 3 (ORMDL3) transgenic mice have reduced levels of sphingolipids including sphingosine-1-phosphate and ceramide.
Department of Medicine, University of California San Diego, La Jolla, Calif.
Marina
M
Miller
Department of Medicine, University of California San Diego, La Jolla, Calif.
Peter
P
Rosenthal
Department of Medicine, University of California San Diego, La Jolla, Calif.
Andrew
A
Beppu
Internal Medicine, Touchstone Diabetes Center, the University of Texas Southwestern Medical Center, Dallas, Tex.
Ruth
R
Gordillo
Department of Medicine, University of California San Diego, La Jolla, Calif. Electronic address: dbroide@ucsd.edu.
David H
DH
Broide
D000818:Animals; D001249:Asthma / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016535:Bronchial Hyperreactivity / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D002518:Ceramides / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008246:Lysophospholipids / Q000235:genetics / Q000378:metabolism*; D008565:Membrane Proteins / Q000235:genetics* / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic; D013107:Sphingolipids / Q000235:genetics / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000235:genetics / Q000378:metabolism
D002518:Ceramides; D008246:Lysophospholipids; D008565:Membrane Proteins; C464399:ORMDL3 protein, human; D013107:Sphingolipids; C060506:sphingosine 1-phosphate; D013110:Sphingosine